The latest price target for Harmony Biosciences (NASDAQ:HRMY) was reported by Cantor Fitzgerald on October 30, 2024. The analyst firm set a price target for $58.00 expecting HRMY to rise to within 12 months (a possible 74.62% upside). 28 analyst firms have reported ratings in the last year.

The latest analyst rating for Harmony Biosciences (NASDAQ:HRMY) was provided by Cantor Fitzgerald, and Harmony Biosciences maintained their overweight rating.

The last upgrade for Harmony Biosciences Holdings Inc happened on October 14, 2022 when Jefferies raised their price target to $61. Jefferies previously had a hold for Harmony Biosciences Holdings Inc.

The last downgrade for Harmony Biosciences Holdings Inc happened on January 2, 2024 when B of A Securities changed their price target from N/A to $30 for Harmony Biosciences Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harmony Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harmony Biosciences was filed on October 30, 2024 so you should expect the next rating to be made available sometime around October 30, 2025.

While ratings are subjective and will change, the latest Harmony Biosciences (HRMY) rating was a maintained with a price target of $51.00 to $58.00. The current price Harmony Biosciences (HRMY) is trading at is $33.22, which is out of the analyst’s predicted range.